Latest news from Macrocure Ltd on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/regenerative-medicine-could-hold-next-steps-in-treating-foot-and-leg-ulcers/?sc=rsin /articles/regenerative-medicine-could-hold-next-steps-in-treating-foot-and-leg-ulcers/?sc=rsin Thu, 06 Nov 2014 08:40:00 EST New and more effective treatments for diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) are sorely needed. One of the today's most promising approaches harnesses regenerative medicine, specifically cell therapy. Israel-based Macrocure Ltd.'s lead product, CureXcell(tm), harnesses living white blood cells, including macrophages, neutrophils and lymphocytes, that are crucial to initiating, promoting and completing the process of cellular regeneration and wound healing for both of these conditions. Macrocure Ltd